
As our mission statement confirms, product safety is the principal concern of Daval International Limited.
Medical practitioners prescribing this unlicensed product under the various national Special Access Schemes are reminded of the fact that most countries operate a Side Effect and Adverse Events Reporting System. In the United Kingdom, the MHRA operates a "Yellow Card" system, which enables swift reporting of adverse effects.
|
|
5th Nov 2009 AIMSPRO receives US orphan-drug designation for ALS |
|
29th Sep 2009 Ceremben Permit Approved |
|
22nd Jul 2009 Patent granted by the OAPI |